Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient
Authors:
- David M. JacobsDJDavid M. Jacobs
- Sara DiTursiSDSara DiTursi
- Jonathan ClausJCJonathan Claus
- Gauri G. RaoGRGauri G. Rao
- 1 August 2016
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 48 (2) , 225-227
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Treatment options for infections caused by carbapenem-resistantEnterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?Expert Opinion on Pharmacotherapy, 2016
- Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological studyThe Lancet Infectious Diseases, 2016
- First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae IsolateAntimicrobial Agents and Chemotherapy, 2015
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemasesThe Lancet Infectious Diseases, 2013
- Rapid detection of carbapenemase genes by multiplex real-time PCRJournal of Antimicrobial Chemotherapy, 2012